Fresh analysis suggests that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who halt conventional lifestyle regimens.
Published data in a major medical journal demonstrates that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users buying such treatments should be informed of the danger of rapid weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a return to original mass within about a year and a half.
Weighing Approaches
The research, which examined 37 of trials involving thousands of patients, compared the outcomes of these new drugs with older methods.
The team emphasize that individuals who lose weight through diet and exercise generally see a slower creep back—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Doctors suggest the way of the drugs is key to understanding the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Issue?
Health authorities suggest the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, due to the high risk of relapse, the therapy might need to be ongoing.
This opinion is echoed by drug manufacturers, who note that the findings "underscore the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Individuals who have discontinued the jabs report a intense resurgence of cravings.
"It was like something flipping and I was suddenly starving," described a patient.
This challenge is compounded if patients have not established permanent dietary or behavioural modifications during therapy.
Widespread Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent solution and lasting health benefits relies on ongoing lifestyle changes.
